Clinical study on FLAG and MEA regimen for refractory or relapsed adult acute myeloid leukemia

( views:545, downloads:0 )
Author:
HE Chen(Department of Hematology, First Affiliated Hospital of Zhengzhou University Medical College, Zhengzhou 450000, China)
GAN Si-lin(Department of Hematology, First Affiliated Hospital of Zhengzhou University Medical College, Zhengzhou 450000, China)
LIU Yan-fang(Department of Hematology, First Affiliated Hospital of Zhengzhou University Medical College, Zhengzhou 450000, China)
XIE Xin-sheng(Department of Hematology, First Affiliated Hospital of Zhengzhou University Medical College, Zhengzhou 450000, China)
SUN Hui(Department of Hematology, First Affiliated Hospital of Zhengzhou University Medical College, Zhengzhou 450000, China)
Journal Title:
Journal of Leukemia & Lymphoma
Issue:
Volume 21, Issue 10, 2012
DOI:
10.3760/cma.j.issn.1009-9921.2012.10.007
Key Word:
Leukemia,myeloid,acute;Relapsed;Refractory;FLAG regimen;MEA regimen

Abstract: Objective To investigate the therapeutic effects and side effects of FLAG and MEA regimen in the treatment of relapsed and refractory adult acute myeloid leukemia.Methods Use retrospective analysis to Observe the therapeutic effects and side effects of the 51 cases of relapsed and refractory adult acute myeloid leukemia (M3 except) from January 2009 to June 2012 in our hospital,which are divided into FLAG group (23 cases) and MEA group (28 cases) according to chemotherapy.Results In FLAG group,the rate of complete remission was 30.4 % (7/23),the rate of partial remission was 17.4 % (4/23),the effective rate was 47.8 % (11/23).In MEA group,the rate of complete remission was 35.7 % (10/28),the rate of partial remission was 21.4 % (6/28),the effective rate was 57.1% (16/28),difference between two groups was not statistically significant. Both groups appeared Ⅳ degrees myelosupression,and there were no significant differences between them on incidences of secondary infection [95.7 % (22/23) vs 89.3 % (25/28)] and haemorrhagia [82.6 % (19/23) vs 85.7 % (24/28)].Difference on cardiac toxicity was statistically significant.Conclusions Compared with MEA regimen, FLAG regimen are similar effective and can be well tolerated,which has lower cardiac toxicity. Thus, FLAG regimen can be used as first-line treatment for relapsed and refractory adult acute myeloid leukemia.

  • [1]朱雄鹏,马跃华,Dekong Liu,等.急性髓细胞白血病治疗新进展:第51届美国血液学年会热点.白血病·淋巴瘤,2010,19:97-102.
  • [2]中华医学会血液学分会.急性髓系白血病(复发难治性)中国诊疗指南(2011年版).中华血液学杂志,2011,32:887-888.
  • [3]张之南,沈悌.血液病诊断与疗效标准.3版.北京:北京科学技术出版社,2009:106-116,131-134.
  • [4]Higashi Y,Turzanski J,Pallis M,et al.Contrasting invitro effeets for the combination of fludarabine, cytosine arabinoside (Ara-C) and granulocyte colony-stimulating factor (FLAG) compared with daunorubicin and Ara-C in P-glyeoprotein-positive and Pglycoprotein-negative acute myeloblastie leukemia. Br J Haematol,2000,111:565-569.
  • [5]Hubeek I.Litvinova E,Peters GJ,et al.The effect of G-CSF on the invitro cytotoxicity of cytarabine and fludarabine in the FLAG combination in pediatric acutemyeloid leukemia. Int J Oncol, 2004,25:1823-1829.
  • [6]Camera A, Rinaldi CR, Palmieri S, et al. Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome (R)) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients.Ann Hematol,2009,88:151-158.
  • [7]华东FLAG方案治疗协作组.氟达拉滨联合阿糖胞苷和粒细胞集落刺激因子治疗复发和难治性急性髓系白血病.中华血液学杂志,2005,26:684-685.
  • [8]张新友,徐肇明,许瑞莲,等.FLAG方案治疗难治性和复发性急性白血病的临床分析.白血病·淋巴瘤,2007,16:199-203.
  • [9]杨斌,曹祥山,王彪,等.FLAG方案与IA方案治疗初治急性髓系白血病临床对比观察.中华血液学杂志,2012,33:141-143.
  • [10]Auberger J, Clausen J, Willenbacher W, et al. Fludarabine/intermediate-dose cytarabine with or without allogeneic hematopoietic stem cell transplantation in poor-risk leukemia:a single center experience.Int J Hematol,2008,87:382-386.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn